Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.

Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES.

Hum Pathol. 2018 Jun;76:133-140. doi: 10.1016/j.humpath.2018.02.019. Epub 2018 Mar 5.

PMID:
29518404
2.

The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality.

Shaverdian N, Wang X, Hegde JV, Aledia C, Weidhaas JB, Steinberg ML, McCloskey SA.

Cancer. 2018 Apr 15;124(8):1673-1681. doi: 10.1002/cncr.31159. Epub 2018 Feb 26.

PMID:
29479673
3.

Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.

Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA.

Clin Breast Cancer. 2018 Apr;18(2):e205-e218. doi: 10.1016/j.clbc.2017.09.010. Epub 2017 Sep 27.

PMID:
29050918
4.

Investigating the association of rs2910164 with cancer predisposition in an Irish cohort.

McVeigh TP, Mulligan RJ, McVeigh UM, Owens PW, Miller N, Bell M, Sebag F, Guerin C, Quill DS, Weidhaas JB, Kerin MJ, Lowery AJ.

Endocr Connect. 2017 Nov;6(8):614-624. doi: 10.1530/EC-17-0196. Epub 2017 Sep 12.

5.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.

Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA.

Breast Cancer Res Treat. 2017 Nov;166(1):145-156. doi: 10.1007/s10549-017-4392-4. Epub 2017 Jul 12.

PMID:
28702891
6.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH.

JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478.

7.

Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein.

Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas JB, Tuck DP, Sweasy JB.

Mol Cancer Res. 2016 Nov;14(11):1068-1077. Epub 2016 Sep 12.

8.

Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9.

Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB.

Noncoding RNA. 2016 Sep 30;2(4). pii: E10. doi: 10.3390/ncrna2040010.

9.

The Non-Coding RNA Journal Club: Highlights on Recent Papers-4.

Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB.

Noncoding RNA. 2016 Sep 21;2(3). pii: E9. doi: 10.3390/ncrna2030009.

10.

cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation.

Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ.

Oncogene. 2017 Jan 26;36(4):512-524. doi: 10.1038/onc.2016.222. Epub 2016 Jun 20.

11.

miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage.

Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB.

Nat Commun. 2016 Mar 21;7:10954. doi: 10.1038/ncomms10954.

12.

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.

McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB.

Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11.

13.

Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase.

Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, Morrical SW.

Nucleic Acids Res. 2015 Jan;43(2):1098-111. doi: 10.1093/nar/gku1337. Epub 2014 Dec 24.

14.

A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA.

Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB.

J Radiat Oncol. 2014 Dec;3(4):371-378.

15.

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S.

Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348.

16.

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB.

Ann Oncol. 2014 Nov;25(11):2230-6. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31. Erratum in: Ann Oncol. 2015 May;26(5):1038-9.

17.

A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.

Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB.

BMC Cancer. 2014 Jun 10;14:421. doi: 10.1186/1471-2407-14-421.

18.

Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.

Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ.

Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9.

19.

Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.

Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ.

Cell Cycle. 2014;13(6):1030-40. doi: 10.4161/cc.27941. Epub 2014 Feb 3.

20.

Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary.

Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):11-7. doi: 10.1016/j.ijrobp.2013.09.040. Epub 2013 Nov 15. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1115.

PMID:
24246724
21.

SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.

Preskill C, Weidhaas JB.

Crit Rev Oncog. 2013;18(4):327-40. Review.

22.

Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.

Kunos CA, Winter K, Dicker AP, Small W Jr, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK.

Int J Gynecol Cancer. 2013 May;23(4):615-21. doi: 10.1097/IGC.0b013e31828b4eb5.

23.

COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.

Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM.

Int J Gynecol Cancer. 2013 Jan;23(1):176-83. doi: 10.1097/IGC.0b013e3182791efc.

24.

SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer.

Salzman DW, Weidhaas JB.

Pharmacol Ther. 2013 Jan;137(1):55-63. doi: 10.1016/j.pharmthera.2012.08.016. Epub 2012 Sep 3. Review.

25.

Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma.

Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704. doi: 10.1073/pnas.1201516109. Epub 2012 Jun 8.

26.

The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.

Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP.

PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25.

27.

A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer.

Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):40-6. doi: 10.1016/j.ijrobp.2012.03.025. Epub 2012 Jun 1.

PMID:
22658441
28.

A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.

Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS.

EMBO Mol Med. 2012 Mar;4(3):206-17. doi: 10.1002/emmm.201100200. Epub 2012 Feb 3.

29.

KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.

Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ.

Cell Cycle. 2012 Jan 15;11(2):361-6. doi: 10.4161/cc.11.2.18794. Epub 2012 Jan 15.

PMID:
22189714
30.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

31.

Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells.

Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ.

Cancer Biol Ther. 2011 Nov 15;12(10):908-14. doi: 10.4161/cbt.12.10.17681. Epub 2011 Nov 15.

32.

KRAS rs61764370 in Epithelial Ovarian Cancer-Letter.

Weidhaas JB, Slack FJ.

Clin Cancer Res. 2011 Oct 15;17(20):6600; author reply 6601. doi: 10.1158/1078-0432.CCR-11-1195. No abstract available.

33.

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.

Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M.

Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12.

34.

miRNAs in the spotlight: Making 'silent' mutations speak up.

Salzman DW, Weidhaas JB.

Nat Med. 2011 Aug 4;17(8):934-5. doi: 10.1038/nm0811-934. No abstract available.

PMID:
21818091
35.

The Holman Research Pathway in radiation oncology.

Weidhaas JB, Kirsch DG.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):321-3. doi: 10.1016/j.ijrobp.2011.01.030. No abstract available.

36.

MicroRNA signatures differentiate melanoma subtypes.

Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB.

Cell Cycle. 2011 Jun 1;10(11):1845-52. Epub 2011 Jun 1.

37.

Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ.

Mol Ther. 2011 Jun;19(6):1116-22. doi: 10.1038/mt.2011.48. Epub 2011 Mar 22.

38.

Cancer microRNAs: from subtype profiling to predictors of response to therapy.

Chan E, Prado DE, Weidhaas JB.

Trends Mol Med. 2011 May;17(5):235-43. doi: 10.1016/j.molmed.2011.01.008. Epub 2011 Feb 25. Review.

39.

MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk.

Blitzblau RC, Weidhaas JB.

Mol Diagn Ther. 2010 Dec 1;14(6):335-42. doi: 10.2165/11587600-000000000-00000. Review.

PMID:
21275451
40.

Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.

Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB.

Cell Cycle. 2011 Jan 1;10(1):90-9. Epub 2011 Jan 1.

41.

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.

Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ.

Oncogene. 2011 Mar 31;30(13):1542-50. doi: 10.1038/onc.2010.536. Epub 2010 Nov 29.

42.

MicroRNA binding site polymorphisms as biomarkers of cancer risk.

Pelletier C, Weidhaas JB.

Expert Rev Mol Diagn. 2010 Sep;10(6):817-29. doi: 10.1586/erm.10.59.

43.

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.

Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB.

Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30.

44.

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB.

Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20.

45.

MicroRNA signatures differentiate uterine cancer tumor subtypes.

Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB.

Gynecol Oncol. 2010 Sep;118(3):251-7. doi: 10.1016/j.ygyno.2010.05.010. Epub 2010 Jun 9.

46.

Regression of murine lung tumors by the let-7 microRNA.

Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ.

Oncogene. 2010 Mar 18;29(11):1580-7. doi: 10.1038/onc.2009.445. Epub 2009 Dec 7.

47.

MicroRNAs as potential cancer therapeutics.

Trang P, Weidhaas JB, Slack FJ.

Oncogene. 2008 Dec;27 Suppl 2:S52-7. doi: 10.1038/onc.2009.353. Review.

PMID:
19956180
48.

MicroRNAs: tools for cancer diagnostics.

Paranjape T, Slack FJ, Weidhaas JB.

Gut. 2009 Nov;58(11):1546-54. doi: 10.1136/gut.2009.179531.

49.

Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.

Weidhaas JB, Li SX, Winter K, Ryu J, Jhingran A, Miller B, Dicker AP, Gaffney D.

Clin Cancer Res. 2009 Jun 15;15(12):4199-206. doi: 10.1158/1078-0432.CCR-08-2257. Epub 2009 Jun 9.

50.

The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells.

Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ.

Oncogene. 2009 Jun 25;28(25):2419-24. doi: 10.1038/onc.2009.106. Epub 2009 May 4. Erratum in: Oncogene. 2009 Aug 20;28(33):3008. Ullrich, R [corrected to Müller, R U].

Supplemental Content

Loading ...
Support Center